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Abstract
CD8 coreceptor expression is tightly regulated during T cell development and is coupled
with the functional phenotype of cytotoxic T cells. Understanding the transcriptional
control mechanisms of Cd8 gene regulation will therefore provide new insights into cell
fate decisions of DP thymocytes towards CD4/CD8 lineage differentiation.
Five developmental stage- and subset-specific Cd8 enhancers were identified in previous
studies. However, some important aspects remain to be adressed. It is still unclear
where the core enhancer regions are located within the known Cd8 enhancers. Since the
Cd8 cis-regulatory elements were initially mapped on large genomic fragments (4-8kb),
it is essential to identify the core enhancer regions within those fragments in order to use
them as molecular baits for the isolation of binding factors. Furthermore, it is not known
which cis-regulatory elements direct the expression of CD8 in CD8αα+ dendritic cells.
Important Cd8cis-regulatory elements are expected to be evolutionary conserved, thus
a cross-species comparison of the Cd8a and Cd8b genomic loci to search for evolutionary
conserved regions (ECR) was performed. This approach led to the identification of 10
ECRs ranging from 200bp to 500bp. In vivo transgenic reporter expression assays and
in vitro transient luciferase assays were performed to test ECR containing fragments for
enhancer activity. These studies led to the identification of the E8I core enhancer and
we could also identify a novel enhancer element (E8VI) that drives expression of Cd8 in
CD8αα+ dendritic cells.
Previous findings of our laboratory demonstrated epigenetic control of the Cd8 gene loci.
We further identified that the transcription factor MAZR acts as a negative regulator of
CD8 expression. In order to learn more about the role of MAZR, we generated MAZR
deficient mice and observed an altered CD4/CD8 ratio in the thymus of MAZR knock-
out mice as well as the development of class I-restricted CD4 lineage cells. Furthermore
we observed an increase of Th-POK expression in MAZR -/- CD4+CD8lo thymocytes,
indicating that MAZR might regulate the expression of Th-POK. By using ChIP experi-
ments we showed that MAZR is binding to the Th-POK silencer region RBS-1, indicating
a molecular mechanism where MAZR is recruited to the Th-POK silencer region RBS-1
and in turn contributes to the appropriate repression of Th-POK expression.
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Zusammenfassung
Die Expression des CD8 Co-Rezeptormoleküls wird während der Entwicklung von T
Zellen streng reguliert und ist an den funktionellen Phänotyp von zytotoxischen T Zellen
gekoppelt. In vorangegangenen Experimenten konnten fünf Cd8 spezifische Enhancer
Elemente identifiziert werden. Nachdem diese Cd8 cis-regulatorischen Elemente ur-
sprünglich als große genomsiche Abschnitte (4-8kb) nachgewiesen wurden, ist es von
großer Bedeutung die Kern-Enhancer Regionen zu identifizieren um diese als moleku-
lare Köder für die Isolation von Bindungsfaktoren zu nutzen. Von wichtigen Cd8 cis-
regulatorische Elemente wird angenommen, dass sie evolutionär konserviert sind und
daher wurde am Cd8 Lokus ein Sequenzvergleich verschiedener Spezies durchgeführt
um evolutionär konservierte Regionen (ECRs) nachzuweisen. Dieses Experiment führte
zur Identifizierung von 10 ECRs in der Größe zwischen 200bp und 500bp. Um die ge-
fundenen Fragmente auf Ihre Enhancerfunktion zu testen wurden in vivo transgene Re-
porter Expressions Analysen zusammen mit in vitro Luciferase Analysen durchgeführt.
Mit Hilfe dieser Experimente konnten wir sowohl den E8I Kern-Enhancer identifizieren
sowie ein neues Enhancer-Element (E8VI), welches die Cd8 Expression in CD8αα+ den-
dritischen Zellen reguliert, lokalisieren.
Bisherige Experimente in unserem Labor zeigten auch, dass der Cd8 Lokus epigenetisch
reguliert wird. Weiters konnten wir den Transkriptionsfaktor MAZR als negativen Reg-
ulator des CD8 Co-Rezeptormoleküls identifizieren. Um mehr über MAZR zu lernen,
generierten wir MAZR knock out Mäuse welche zu einem veränderten CD4/CD8 Verhält-
nis im Thmyus führten und die Ausbildung von MHC-Klasse I selektierten CD4 Zellen
zeigte. Des Weiteren konnten wir einen Anstieg der Th-POK Expression in MAZR -/-
CD4+CD8lo Thymocyten feststellen, dass einen Hinweis darauf gibt, dass MAZR in der
Regulierung der Th-POK Expression beteilig ist. Durch ChIP-Experimente konnten wir
zeigen dass MAZR an die Th-POK silencer Region RBS-1 bindet. Daher schlagen wir
einen molekularen Mechanismus vor, bei dem MAZR an die Th-POK silencer Region
RBS-1 rekrutiert wird um die Th-POK Expression zu unterdrücken.
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1 Introduction
1.1 T cell development: starting from scratch
Haematopoietic stem cell (HSC)-derived lymphocyte progenitors migrate from the bone
marrow through the blood stream to the thymus, the primary site of T cell lym-
phopoiesis.1 Different developmental stages of thmyocytes can be distinguished on the
basis of the expression of CD4 and CD8 co-receptor molecules.2 After common lymphoid
progenitors enter the cortico-medullary junction of the thymus they become double neg-
ative (DN, CD4−CD8−) cells (Figure 1.1). This stage can be further subdivided into four
stages of differentiation regarding CD44 and CD25 expression: DN1 (CD44+CD25−),
DN2 (CD44+CD25+), DN3 (CD44−CD25+), and DN4 (CD44−CD25−).3 As cells prog-
ress through the DN2 to DN4 stages, they express the pre-T-cell receptor (TCR) which
is composed of the non-rearranging pre-Tα-chain and a rearranged TCRβ-chain.4 Suc-
cessful pre-TCR expression leads to substantial cell proliferation during the DN3/DN4
stage and the cells become CD8+ immature single-positive (ISP) cells. After express-
ing CD4 co-receptor molecules the cells are termed double positive (DP, CD4+CD8+)
thymocytes and the replacement of the pre-TCR α-chain with a newly rearranged TCR
α-chain results in the expression of a mature αβ-TCR. The αβ-TCR+CD4+CD8+(DP)
thymocytes then interact with cortical epithelial cells that express a high density of
MHC molecules associated with self-peptides.5 Most DP thymocytes (90%) express
TCRs that bind with a low avidity to MHC-self peptide complexes and the intracellular
signals that are required to sustain viability are not generated, and the cells undergo
apoptosis (death by neglect). A small fraction of immature T cells (5%) sustains TCRs
that bind with a high avidity to MHC-self peptide complexes. These thymocytes are
potentially autoreactive and therefore are eliminated by rapid apoptotic death (nega-
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Figure 1.1: T cell development in the thymus. The thymic architecture is orga-
nized into cortex and medulla, each of which is characterized by the presence of thymocyte
precursors at defined maturation stages and particular stromal cell types.6 Thymocyte
differentiation is characterized by the cell surface markers CD4, CD8, CD44, and CD25
as well as the status of the T-cell receptor.3,7, 8
tive selection). Cells that express TCRs that recognize self-ligands and generate signals
with an intermediate avidity for MHC-self peptide complexes undergo a process called
positive selection.5 Thymocytes that express TCRs that bind self-peptide–MHC-class-I
complexes become CD8+ cytotoxic T cells, whereas those that express TCRs that bind
self-peptide–MHC-class-II ligands become CD4+ helper T cells.5 The positive selected
naive αβ T cells emigrate after 4 – 5 days through a “conveyor belt” mechanism, where
the oldest thymocytes leave the thymus first to migrate to peripheral lymphoid sites.9
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1.2 The murine Cd8ab gene complex
1.2.1 Cis-regulatory elements
Thymus-derived cytotoxic T cells (CTLs) express the cell surface glycoprotein CD8 that
consists of CD8α and CD8β heterodimers. Nonconventional T cells such as intraep-
ithelial lymphocytes (IELs) from the gut,10,11 a subset of human natural killer (NK)12
cells, and CD8+ dendritic cells (DCs)13 express only CD8αα homodimers. Mice with a
disrupted Cd8a gene can not express the CD8 heterodimer and therefore lack mature
CTLs, indicating that CD8 is crucial for thymocyte development.14 Removal of the
cytoplasmic domain of the CD8β-chain15 or deletion of the Cd8b gene16 resulting in dis-
ruption of positive and negative selection in thymocytes. This expression pattern of the
Cd8a and Cd8b genes, which are linked at a distance of 36 kb on mouse chromosome 617
, indicates that their expression must be both coordinately and independently regulated.
Therefore, cis-regulatory elements that are specific for CD8α or CD8β might exist.18
A DNase I Hypersensitivity (DH) analysis of an 80 kb region in the murine Cd8 loci iden-
tified four clusters (I, II, III, IV) of DH sites, whereas three of them are thymocyte specific
(II, III, IV).19 Transgenic mice carrying the identified Cd8ab genomic locus, expressed
the transgenic CD8 in a developmental stage- and lineage-specific manner, showing that
the main cis-regulatory elements are active in this 80kb region.2,19 Additional transgenic
reporter-expression assays led to the identification of at least five genomic fragments that
are involved in the regulation of Cd8a and Cd8b gene expression.19–29 These results re-
vealed a complex regulatory network that involves the developmental stage-, subset-,
and lineage-specific use of multiple closely linked cis-regulatory elements during T-cell
development2 (Figure 1.2).
The results from the transgenic reporter expression assays raised the question of why so
many different, and probably partially redundant, cis-acting elements are required for
the regulation of CD8 expression. One could argue that embedded within the endoge-
nous Cd8 gene loci, the enhancers which show activity in the same subsets, such as E8I
and E8II in CD8 SP and mature CD8− T cells and E8II and E8III in DP thymocytes, are
together required for high-level expression of CD8α and CD8β.22,24,28 When analyzed
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Figure 1.2: Mouse Cd8a and Cd8b genomic loci: transgenic constructs and
enhancer deletions. Upper panel – genomic organization of the Cd8ab gene complex
including the localization of DNase I hypersensitivity clusters (CI-CIV). Individual DH
sites are indicated by vertical arrows. Horizontal arrows indicate the position and the
transcriptional orientation of the Cd8a and Cd8b genes. Thick bars below the diagram
represent genomic fragments used to define the Cd8 cis-regulatory elements (E8I-E8V).
All BamHI (B), but only relevant EcoRI (E) restriction sites are shown. Middle panel
– grey bars represent the key genomic fragments used to identify Cd8 enhancers. the
table on the left indicates the developmental stage-, and lineage- specific activity of in-
dividual transgenic constructs. For intraepithelial lymphocytes (IELs) only expression
in the CD8αα lineage is shown. Lower panel – red bars represent mouse germline dele-
tions of CD8 genomic fragments. The effect on the CD8 expression is shown on the
right. +, normal expression; +/-, reduced expression; var, variegated expression; nd, not
determined.2
in transgenic reporter assays isolated from their genomic context, they therefore display
similar activities. Another possible reason for the requirement of multiple cis-elements
is if some of the enhancers direct specifically the expression of either CD8α or CD8β.
Based on the results from transgenic reporter expression assays, one would have pre-
dicted that individual deletions of enhancers should (at least) lead to a reduction of
CD8 expression in the subsets in which the enhancers show activity, and that combined
deletions of enhancers with similar T cell subset activities should lead to a more dramatic
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reduction of CD8 expression compared to individual deletions. Dependent on whether
some of the enhancers are specific for CD8α or CD8β, one may also expect a reduction
in the expression of only one of these co-receptor genes.
1.2.2 Single and combinatorial deletions of cis-regulatory elements
Because it is difficult to experimentally test these possibilities in transgenic reporter
assays, a systematic deletional analysis of the various enhancers and cis-elements in the
mouse germ line has been initiated (Figure 1.2). Initial studies focused on the following
cis-regulatory regions: Enhancer E8I (overlapping with cluster III, DH sites 1 and 2 also
termed CIII-1,2 which is active as a transgene in CD8+ SP T cells and IELs; enhancer
E8II (CIV-4,5) directed expression in DP and CD8+ SP T cells; E8III (CIV-3) was active
only in immature DP thymocytes; E8IV (CIV-1,2) displayed low expression in CD4+ SP
and mature T cells and directed expression in DP and CD8 lineage cells; and DH cluster
II(E8V; CII-1,2) which by itself has no enhancer activity, but in combination with cluster
III directs expression in mature CD8+ T-cell lineage and in DP thymocytes.22,24 Mice
homozygous for deletion of E8I had a 3-5 fold reduction in Cd8α expression levels on
IEL indicating that E8I is the major regulatory element for Cd8α expression on IEL.22
However, E8I deficient mice showed a normal expression pattern of Cd8a and Cd8b genes
in thymic-derived T cells. Mice with targeted deletions in E8II had normal expression
of Cd8α and Cd8β in conventional T cells and IELs.28 These results together showed
that individual deletions of either E8I or E8II did not cause any change in the expression
pattern of CD8 in the various T cell subsets. Previous experiments with transgenic mice
showed that E8I and E8II individually direct expression of Cd8α and Cd8β in mature
CD8+ T cells and so it might be possible that these two enhancers can compensate for
each other.2 In addition, in E8II-deficient mice, E8III or E8V (in combination with other
regulatory regions) could similarly compensate to direct CD8 expression in DP thymo-
cytes.22,24
In order to address the question if enhancers can compensate for each other, E8I and
E8II double-deficient mice were generated. In contrast to individual deletions, the dele-
tion of both enhancers had a major effect on the expression of CD8 during thymocyte
10
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development, but not in mature CD8 lineage cells.28 A population of CD8−CD4+ (CD8
negative DP) thymocytes were observed that could not be distinguished from DP thy-
mocytes by surface marker expression and functional phenotype. The presence of CD8
negative DP thymocytes indicates that the Cd8a and Cd8b gene expression is variegated
in DP thymocytes.28 Strikingly, a similar population of CD8 negative DP thymocytes
were identified by deletion of E8V or by altering the activity of either the Ikaros family
of transcriptional regulators or the BAF (Brahma-related gene/Brahma-associated fac-
tor) chromatin remodelling complex.29–31 These results indicate that the CD8 enhancers
may also function as recruitment sites for factors involved in chromatin remodeling to
activate the Cd8a and Cd8a gene loci during the DN to DP transition in T cell devel-
opment.2
In more recent studies we have compared the epigenetic state of the Cd8α and Cd8β
gene loci in sorted CD8 negative DP and DP thymocytes isolated from E8I,E8II doubly
deficient mice.32 Chromatin immunoprecipitation (ChIP) assays and DNA methyla-
tion analysis revealed that CD8 negative DP thymocytes have epigenetic modifications
at the Cd8a and Cd8b gene complex that correspond to an “off” state of chromatin.
Variegation of CD8 expression in DP thymocytes could be partially reverted by in-
tercrossing E8I,E8II doubly deficient mice with conditional DNA methyltransferase 1
(Dnmt1)-deficient mice,33 further indicating a partial “epigenetic block” of CD8 expres-
sion due to the absence of cis-regulatory elements. Taken together, these studies link
Cd8 enhancer function with the epigenetic regulation of CD8 expression. Surprisingly,
expression of CD8 on those cells in which it was up-regulated (i.e. DP thymocytes and
peripheral CD8+ T cells) was only slightly reduced in the mutant mice. Thus, it is pos-
sible that other (novel) Cd8 enhancers than E8I, E8II, and E8V are required to maintain
expression of CD8 once the expression has been initiated, or that epigenetic mechanism
renders mature T cells independent of further function of these cis-regulatory elements.
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1.3 Transcription factors in the epigenetic control of the Cd8ab
gene loci
1.3.1 MAZR: A negative regulator of CD8 expression in DN T cells
MAZR (Myc-associated Zinc finger related factor) was originally isolated as an interac-
tion partner of Bach2, a transcriptional repressor in B cells and neuronal cells.34 The
MAZR transcription factor (641aa) is encoded by the Zfp278 gene and contains a N-
terminal BTB-POZ motif and seven C2H2 zinc fingers (Figure 1.3). The BTB (broad
complex, tramtrack, bric a brac) domain or POZ (poxvirus zinc finger) domain, is a
protein–protein interaction motif that was first identified in the fruit fly drosophila
melanogaster and is present in about 200 genes in mammalian genomes.35,36 Proteins
with a BTB domain are involved in a number of cellular processes such as protein
targeting for ubiquitination, cytoskeleton dynamics, and transcriptional regulation.35
Among all proteins containing a BTB domain a large group of proteins have also C2H2
zinc finger (ZF, Krüppel-like C2H2 type) motifs that are important for DNA binding.37
BTB-ZF proteins can either form oligomers or heteromers with other BTB-ZF proteins
and have been mainly associated with transcriptional repression.34,38,39 Until now, six
BTB-ZF have been identified to play a role in T cell development and/or T cell func-
tion: MAZR,32 Th-POK (cKrox),40,41 PLZF,42 Bcl6,39 ROG (PLZP/TZFP/FAZF),43
and BAZF (Bcl6b).44
MAZR is expressed in many tissues, including fetal liver, bone marrow and thymus and
was first isolated in a yeast one-hybrid screen in a search for Cd8 enhancer E8II binding
proteins.32 We have previously shown that MAZR is highly expressed in DN thymocytes
where it is interacting with N-CoR corepressor complexes, but as thymocyte develop-
ment progress MAZR expression is down modulated and almost no expression of MAZR
could be found in peripheral T cells. Forced expression of MAZR affect the activation of
CD8 expression in a proportion of DP thymocytes and resulting in a variegated expres-
sion of CD8.32 Previous studies have described that transcription factors together with
chromatin-modifying complexes can alter the epigenetic pattern at the closely linked
Cd8a and Cd8b gene loci to a transcriptional “on” state and thereby facilitating expres-
12
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Figure 1.3: MAZR (Myc-associated Zinc finger related factor). The transcrip-
tion factor MAZR with its N-terminal BTB domain (green) and seven C2H2 zinc fingers
(orange). The alternative variant of MAZR lacks the last zinc finger.
sion.31,45 In contrast, it might be that cells with variegated CD8 expression keeping the
local chromatin at the Cd8 gene loci in a transcriptional “off ” state at the DN stage.
Recently our group generated MAZR deficient mice and we observed an altered CD4/CD8
ratio in the thymus as well as redirection of class I-restricted thymocytes into the CD4+
lineage (Sakaguchi et al. manuscript in preparation). Furthermore, we detected a three
fold increase of Th-POK expression in MAZR -/- CD4+CD8lo thymocytes, indicating
that MAZR might regulate Th-POK expression. Taken our results together we propose
a model were MAZR is a critical negative regulator of CD8 expression32 and is also
involved in CD4/CD8 lineage commitment.
1.3.2 Th-POK: A master regulator of CD4 T cells
The BTB-ZF factor Th-POK (T-helper-inducing POZ/Kruppel like factor; also termed
cKrox; encoded by the Zbtb7b gene) contains a N-terminal BTB domain and four C2H2
zinc finger motifs.40 Recently, a spontaneous mouse mutant (helper-deficient (HD)
mouse) has been reported in which the commitment to the CD4+ helper T cell lin-
eage was diminished without any defects in positive selection.46,47 The mice with single
recessive HD mutation showed a normal CD4 and MHC-II expression as well as a proxi-
mal intact TCR signaling.46,47 It has been found that a single base pair mutation in the
second zinc finger of Th-POK redirects all class-II restricted thymocytes to the CD8+
cytotoxic lineage.40 Strikingly, transgenic expression of Th-POK in the thymus lead to
redirection of all positively selected thymocytes to differentiate into CD4+ T cells, even
13
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those with MHC class I-restricted TCRs.40,41 When the mutated (HD) form of Th-POK
or a truncated version lacking the BTB domain was overexpressed in thymocytes no
effect was observed.40,41 This indicates that the HD mutation plays a crucial role in
the ZF DNA-binding domain for the proper function of Th-POK during CD4 lineage
development. Therefore Th-POK is termed as master regulator of CD4-lineage choice
and CD4+ T-cell differentiation48 (Figure 5.1). Th-POK influences both Cd4 and Cd8
gene transcription. At the Cd4 locus, Th-POK maintains Cd4 gene transcription by
preventing factors, such as RUNX3, from silencing49 , whereas Cd8 gene expression is
decreased by downregulating the enhancer activity of E8I.50
1.3.3 RUNX: A negative regulator of Th-POK
RUNX (AML, acute myeloid leukaemia) proteins belong to the Runt-domain family of
transcription factors that share similar structural organization as well as conserved DNA-
binding sites.51 The three mammalian RUNX genes (RUNX1, RUNX2, and RUNX3)
are known to encode for transcription factors that bind DNA as part of the core-binding
factor (CBF) complex. Together with the CBFβ cofactor, the CBF complex activates
and represses transcription of key regulators of survival, growth and differentiation path-
ways.52 In the thymus, RUNX1 is mainly expressed in DN thymocytes whereas RUNX3
expression was observed in CD8+ SP thymocytes.49 Previous studies showed that both
RUNX1 and RUNX3 bind to the Cd4 silencer element and silence Cd4 gene transcrip-
tion and therefore indicating a role of RUNX proteins in CD4/CD8 lineage choice.49
In thymocyte development, RUNX3 is first expressed in CD4+CD8lo intermediate thy-
mocytes and is upregulated in CD8+ T cells.53,54 During T cell differentiation, RUNX3
binds to the Cd4 silencer element to silence Cd4 gene transcription,49 and at the same
time RUNX3 is binding to E8I at the Cd8 gene loci and reinitiates Cd8 gene transcrip-
tion.53 Recent data showed that RUNX proteins can also bind to Zbtb7b, the gene
that encode for Th-POK, and shut down Th-POK expression.55 Thus, RUNX proteins
promote Cd8+ T cell differentiation in a variety of possible control mechanisms.
14
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1.4 Aims of the master thesis
As outlined in the introduction, five developmental stage- and subset-specific-Cd8 en-
hancers (EI - EV) have been identified and extensively studied in transgenic reporter
expression assays and by deletional analysis in the mouse germ line. These results re-
vealed important insights into epigenetic and transcriptional control mechanisms during
T cell development. Nevertheless, several important aspects remain to be adressed. The
core enhancer regions for most of the known Cd8 enhancers have not been described.
This would be important to use the Cd8 enhancers as molecular baits to identify binding
factors. In addition, it is not known which cis-regulatory elements direct the expression
of CD8 in CD8αα+ dendritic cells. Previous findings in our laboratory demonstrated
epigenetic control of the Cd8ab gene loci by a complex network of transcription factors.
Nevertheless, it is still poorly understood how these transcription factors are regulated
during T cell development. Therefore, we revisited the Cd8ab gene complex to gain more
insight into the complex regulated Cd8 gene loci by using a combination of bioinformatic
and molecular biology approaches.
Specific aim 1 was to identify the E8I core enhancer region and novel Cd8 en-
hancer elements within the Cd8ab gene complex. Since the identified enhancer
elements are 4-8 kb in length it is crucial to find the core enhancers in order to use
them as molecular baits for the identification of binding factors. It is expected that
important Cd8 cis-regulatory elements are evolutionary conserved. Thus we performed
a cross-species comparison of the Cd8a and Cd8b genomic loci to identify evolution-
ary conserved regions (ECRs). Furthermore we wanted to test the identified ECRs for
enhancer activity and thus we used a combination of an in vitro transient luciferase
reporter assay and an in vivo transgenic reporter assay.
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Specific aim 2 was to identify the role of MAZR in the regulation of CD4/CD8
lineage commitment. We have previously shown that the transcription factor MAZR
is a negative regulator of CD8 expression. In ongoing studies in the laboratory we
observed an altered CD4/CD8 ratio in the thymus of MAZR deficient mice. Further-
more, we detected a three fold increase of Th-POK expression in MAZR -/- CD4+CD8lo
thymocytes, indicating that MAZR might regulate Th-POK expression. In order to
investigate that in more detail we performed Chromatin-Immunoprecipitation (ChIP)
experiments of the Th-POK silencer region RBS-1 as well as Co-Immunoprecipitation
of MAZR and RUNX3.
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2.1 Cis-regulatory elements in the Cd8ab gene locus
2.1.1 Evolutionary conserved regions (ECRs) in the Cd8ab gene locus
It has been shown that important cis-regulatory elements are evolutionary conserved.56
Therefore we asked the question, if this is also the case for the Cd8ab gene complex and
performed a bioinformatic cross-species comparison. By using the algorithm MULAN
(http://mulan.dcode.org/)57 we compared the sequences of the Cd8a and Cd8b gene
loci of mouse, human, rat and dog, respectively. The evolutionary conserved regions
(ECRs) were defined as regions having more than 70% homology over a stretch of at
least 100bp. 10 ECRs in the range of 200-500bp that matched the selection criteria were
identified (Figure 2.1). Strikingly, ECR-2, -3, -6, -7, -8 and -10 overlapped with previ-
ously identified enhancer elements whereas ECR-3 and -8 also correlates with DNase I
Hypersensitivity sites (HS) at the Cd8ab gene complex. To our surprise we also iden-
tified ECR-1, -4, -5, and -9 as novel elements that have never been described in the
literature before. In order to test the ECRs for enhancer activity we performed both
in vitro transient luciferase assays of ECR-4, -5 and -9 and in vivo transgenic reporter
assays of ECR-4, -5, and -8.
2.1.2 Identification of the E8I core enhancer region
Recent studies identified a 1.6kb HindIII fragment22 that shows the same enhancer ac-
tivity as the original 7.6kb enhancer E8I fragment.21 By using the MULAN algorithm we
identified ECR-8, a 200bp region that overlaps with the 1.6kb HindIII fragment and the
hypersensitivity site CIII-2 of enhancer E8I (Figure 2.1). Since the enhancer elements are
4-8 kb in length it is crucial to find the core enhancers in order to use them as molecular
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Figure 2.1: Genomic organization of the Cd8a and Cd8b genomic loci. Upper
panel - Schematic map of the Cd8a and Cd8b gene loci. Horizontal arrows indicate
the transcriptional orientation of the Cd8a and Cd8b genes. Vertical arrows indicate
the localization of DNase I hypersensitivity (DH) sites that constitute clusters II, III,
and IV. The horizontal thick bars below DH sites indicate genomic fragments used to
define enhancers E8I, E8II, E8III, E8IV, and E8V, respectively. All BamHI (B), but only
relevant EcoRI (E) sites are shown. Lower panel - Evolutionary conserved non-coding
regions within the Cd8a and Cd8b genomic loci. Pairwise comparison of mouse with dog,
human, and rat, respectively. ECRs (1-10) are indicated by the open boxes. Intergenomic
sequences are shown in red. Degree of homology within exon sequences is indicated in
blue, UTRs in yellow, and intronic sequences in pink.
bait. Therefore, we cloned a small genomic fragment (539bp) containing ECR-8 into a
basic hCD2 reporter construct (Figure 4.2). We used a larger fragment than the 200bp
ECR-8 since there was also a high-degree of homology in the 300bp downstream of ECR-
8. Transgenic mice were generated and positive founders were tested. The analysis of
ECR-8 transgenic mice showed that ECR-8 directs hCD2 expression in mature CD8+
SP thymocytes, peripheral CD8+ T cells and in CD8αα+ IEL (Figure 2.2). The same
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Figure 2.2: Schematic map of the genomic fragments used for in vivo trans-
genic reporter gene expression assays and Flow cytometric analysis of ECR-8
transgenic mice. Upper panel - Schematic map of the Cd8a and Cd8b gene loci and
of the genomic fragments used for the generation of transgenic mice (TG-b, -8, -ECR-
8). The length of the genomic transgenic inserts and the number of transgenic founders
expressing hCD2 among total founders are shown at the right. Lower panel - Flow cy-
tometric analysis of ECR-8 transgenic mice. Dot blots show CD4 vs. CD8 expression
pattern in thymocytes (left panel) and lymph nodes (middle panel) of ECR-8 transgenic
mice. Human CD2 expression is shown in the histograms next to the dot plots. Left
panel shows CD8α vs. CD8β expression in IEL. Histograms show hCD2 expression in
CD8αα+ and CD8αβ+ IEL.
expression pattern was observed with the original large E8I fragment, indicating that
the genomic fragment that contains ECR-8 represents the E8I core enhancer.
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2.1.3 Identification of the novel Cd8-cis regulatory element E8VI
To test whether ECR-4 (246bp), -5 (115bp) and -9 (119bp) have enhancer activity, we
performed in vitro luciferase assays. ECR-4 is located downstream of Cd8 enhancer
E8II and overlaps with the HS site CIV-6 (Figure 2.1). In contrast, ECR-5 and ECR-9
do not overlap with known HS sites. The three evolutionary conserved regions were
inserted in the basic Cd8 promoter luciferase reporter construct (Figure 4.3) and were
transiently transfected either into AKR1.1 cells (DP T cell line) or 1200M cells (CD8+
T cell lymphoma cell line) (Figure 2.3). Neither ECR-4 nor ECR-5 and -9 could drive
the expression of the luciferase gene in vitro, indicating that these fragments have no
enhancer activity at least in these particular cell lines.
Figure 2.3: Luciferase assay of ECR-4, ECR-5 and ECR-9 in AKR1.1 and
1200M cells. Upper panel - Reporter constructs are shown on the left side and were
transfected into AKR1.1 cells. Normalized luciferase expression is shown by bars on the
right side. Lower panel - The reporter constructs were transfected into 1200M cells. The
empty vector was used as the background control whereas the E8II construct was used
as a positive control.Data are representative of two independent experiments.
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Previous studies of the E8I core enhancer did not reveal any enhancer activity in vitro
(Sakaguchi et al., unplublished), although the element was active in transgenic reporter
assays in vivo. Therefore it remained possible that ECR-4 and -9 still show enhancer
activity in vivo. ECR-4 and ECR-9 were inserted in the basic Cd8 promoter transgenic
reporter construct (Figure 4.2) and transgenic mice were generated. For ECR-9, five
human CD2 transgenic founders were obtained. Human CD2 expression could not be
detected in thymocytes and peripheral T cells of ECR-9 founders (data not shown),
indicating that ECR-9 is not a cis-regulatory element that contains enhancer activity
(at least if tested individually). In contrast, hCD2 expression was detected in peripheral
CD8+ but not in CD4+ T cells in 2 out of 11 ECR-4 transgenic founders (data not
shown). This indicated that ECR-4 has enhancer activity specifically in CD8+ T cells.
To test whether ECR-4 is also active during T cell development, transgenic ECR-4 lines
were analyzed in more detail. This revealed that ECR-4 was active in mature CD8 SP
thymocytes and in CD8 T cells but not in immature DP cells. Furthermore we could
not detect hCD2 expression in both CD8αα+ or CD8αβ+ IEL (Figure 2.4). Another
population that express CD8 are CD11c+ CD8αα+ dendritic cells (DCs). Surprisingly,
we observed that ECR-4 can drive hCD2 expression in this specific cell population (Fig-
ure 2.5).
Figure 2.4: Flow cytometric analysis of ECR-4 transgenic mice. Dot blots show
CD4 vs. CD8 expression in thymocytes (left panel) and splenocytes (middle panel) of
ECR-4 transgenic mice. Human CD2 expression is shown in the histograms next to the
dot plots. Left panel shows CD8α vs. CD8β expression in IEL. Histograms show hCD2
expression in CD8αα+ and CD8αβ+ IEL.
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Figure 2.5: Flow cytometric analysis of splenic CD11c+ DC in ECR-4 trans-
genic mice. Dot blots show CD4 vs. CD8 expression pattern on Cd11c-gated spleno-
cytes. Human CD2 expression in non transgenic controls and in ECR-4 transgenic mice
is shown in histograms next to the dot plot.
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2.2 The role of MAZR in regulation of CD4/CD8 lineage
commitment
2.2.1 MAZR binds to Th-POK silencer region RBS-1
Recently, we have shown that MAZR is a negative regulator of CD8 expression and
an altered CD4/CD8 ratio in the thymus has been observed in MAZR deficient mice.
Furthermore we observed that there is redirection of class I-restricted thymocytes into
the CD4+ lineage (Sakaguchi et al., unpublished). Real time PCR analysis of MAZR
knockout mice revealed a three fold increase of Th-POK expression in MAZR -/- CD4+
Cd8lo thymocytes, indicating that MAZR might regulate Th-POK expression.
Figure 2.6: Overview of the Th-POK gene locus. Upper panel - Th-POK gene
locus including RBS-1 silencer element (orange) and the RBS-2 enhancer element (green).
Horizontal arrow indicates the transcriptional start of the Th-POK gene. Lower panel -
Sequence of the Th-POK silencer region RBS-1. The Th-POK core region is indicated in
grey.58 Potential MAZR binding sites are indicated in blue. Red boxes signal missmatches
compared to known MAZR binding sites. RUNX sites are shown in green.
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The expression of Th-POK is repressed during differentiation of MHC class I-restricted
thymocytes toward CD8+ cytotoxic T cells by the Th-POK silencer. Therefore we anal-
ysed the Th-POK silencer region RBS-1 for potential MAZR binding sites. We detected
three MAZR and two RUNX binding sites within the Th-POK silencer region RBS-1
(Figure 2.6).
To test if MAZR binds to the Th-POK silencer region RBS-1, ChIP experiments were
performed. Therefore we used MAZR serum for the Immunoprecipitation followed by
a PCR analysis of the RBS-1 sequence. Strikingly, we identified MAZR binding to the
Th-POK silencer region RBS-1 in MAZR +/+ mice. As a negative control we used
MAZR -/- mice (Figure 2.7).
Figure 2.7: Chromatin-Immunoprecipitation of MAZR on the Th-POK si-
lencer RBS-1. MAZR +/+ (left) and MAZR -/- (right) mice were used for the ChIP
experiment. The input dilutions were as follows; undiluted, 1:5, 1:25. MAZR Preserum
was used as negative control.
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2.2.2 RUNX3 binds to Th-POK silencer region RBS-1 independent of MAZR
Recent data showed that RUNX proteins can also bind to Th-POK silencer region RBS-
1 and shut down Th-POK expression.55 As mentioned before RUNX complexes are
composed of two subunits: the DNA binding domain and the unique non-DNA binding
CBFβ protein. We performed a CBFβ2 ChIP experiment to test if RUNX3 binding to
the Th-POK silencer region RBS-1 is dependent on the expression of MAZR. We could
detect binding of RUNX3 to the Th-POK RBS-1 locus in wildtpye and MAZR deficient
mice. This result indicates that MAZR is not necessary for proper RUNX3 binding
(Figure 2.8).
Figure 2.8: Chromatin-Immunoprecipitation of CBFβ2 on the Th-POK si-
lencer RBS-1. MAZR +/+ (left) and MAZR -/- (right) mice were used for the ChIP
experiment. The input dilutions were as follows; undiluted, 1:5, 1:25. dH2O was used as
negative control.
2.2.3 MAZR does not interact with the RUNX3
After we have identified MAZR binding next to the RUNX sites within the Th-POK
silencer region RBS-1 we wanted to determine whether MAZR can directly interact
with RUNX3. Therefore we overexpressed MAZR and myc-tagged RUNX3 in 293T cells
and performed Co-Immunoprecipitation experiments. These experiments revealed that
MAZR does not interact with RUNX3 (Figure 2.9).
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Figure 2.9: Co-Immunoprecipitation of MAZR and RUNX3. Immunoblots of
Immunoprecipitated (IP) samples and whole cell lysates (WCL) are shown. We used
293T cells where either none, MAZR or myc-tagged RUNX3 or both proteins were over-
expressed.Whole cell lysates were used as a control for the expression of the proteins.
Actin was used as a control of protein loading.
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3.1 The core enhancer region of E8I and a novel Cd8 enhancer
element within the Cd8ab gene complex.
The expression of CD8 is coupled to the phenotype of cytotoxic T cells. Recent studies
identified five developmental stage-, subset-, and lineage-specific Cd8 enhancers that are
involved in the regulation of Cd8a and Cd8b gene expression. A better understanding
how the cis-regulatory elements are functioning and the knowledge of the factors that
bind to the cis-regions within the enhancers will therefore provide molecular details of
lineage commitment and T cell development.
In order to study the murine Cd8ab gene complex, we used a combination of bioin-
formatic and molecular biology approaches. Since the Cd8 cis-regulatory elements were
initially mapped on large genomic fragments (4-8kb),21,22,28 it is important as a first
step to identify the core enhancer regions within those fragments in order to use them
as molecular baits for the isolation of binding factors. Important Cd8 cis-regulatory
elements are expected to be evolutionary conserved, thus we performed a cross-species
comparison of the Cd8a and Cd8b genomic loci to search for evolutionary conserved
regions (ECR). First, we focused on enhancer E8I that is localized initially on a 7.6 kb
BamHI genomic fragment.21 This approach led to the identification of a 539bp fragment
(ECR-8) which overlapped with the hypersensitivity site CIII-2 of enhancer E8I. Several
studies showed that DH sites indicate the location of promoters and enhancers of genes,
including those cis-elements that control expression of the Cd4, Cd8a and Cd8b loci.2,19
Thus, indicating that the DNA sequence of the ECR-8 region has open chromatin status
and is accessible for binding of transcription factors. By performing in vivo transgene
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reporter assays with a reporter construct containing the 539-bp genomic fragment we
identified enhancer activity in CD8+ SP thymocytes, peripheral CD8+ T cells and in
CD8αα+ IEL. The same expression pattern was observed with the original large E8I
fragment, indicating that the genomic fragment that contains ECR-8 represents the E8I
core enhancer.
In addition to the five known CD8 enhancer elements, we focused also on the ques-
tion if we can identify novel enhancer elements within the Cd8ab gene loci. Therefore
we used the cross-sequence comparison to search for novel ECRs and identified three
ECRs (ECR-4, -5 and -9) that mapped outside known enhancer elements (Figure 2.1).
We performed in vivo transgenic reporter assays of ECR-4 and ECR-9. By using a re-
porter construct containing the 246bp (ECR-4) fragment we identified enhancer activity
of hCD2 in mature CD8 SP thymocytes and in CD8 T cells but not in immature DP cells
(Figure 2.4). The new cis-regulatory element was named E8VI (Figure 3.1). Transgenic
founders which had the ECR-9 fragment integrated into their genome did not show any
hCD2 expression.
Figure 3.1: Updated map of enhancer regions located within the Cd8a and
Cd8b genomic loci. Schematic map of the Cd8a and Cd8b gene loci including the novel
enhancer element E8VI in red.
By performing in vitro luciferase assays of ECR-4, -5 and -9 we were not able to detect
luciferase activity in 1200M and AKR1.1 cells (Figure 2.3). In previous studies of the
E8I enhancer we also could not reveal any enhancer activity in vitro (Sakaguchi et al.,
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unpublished), although the element was active in transgenic reporter assays in vivo. One
reason could be that factors binding to these ECRs are not present in these cell lines
and therefore they can not express the reporter gene. Another reason might be that
cis-elements are only active when they are present in defined chromatin structures. A
developmental programming of the cis-elements might be necessary to obtain enhancer
activity.
Another population that express CD8 are CD11c+ CD8αα+ DCs.13 However, neither E8I
nor E8II was able to direct the expression of a reporter gene in dendritic cells (Ellmeier
et al., unpublished). A more precise analysis of the positive E8VI transgenic founders
revealed expression of hCD2 also in CD8αα+ DCs and E8VI is to our knowledge the first
Cd8 cis-element that is described to be active in CD8αα+ DCs (Figure 3.1).
Comparing E8I and E8VI shows that they have similar activities in cytotoxic T cells
(Figure 3.2). Targeted deletion of E8I resulted in a dramatic loss of CD8α expression in
IEL, but the expression in conventional T cells was normal in the absence of E8I. Based
on our preliminary results, it is conceivable that E8VI may compensate for loss of E8I.
Figure 3.2: Map of transgenic ECR constructs and the summary of their
activity in various T cell lineages.Left panel - Schematic map of the transgenic con-
structs. Right panel - Expression pattern of the hCD2 reporter gene. nd: not determined
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In the future, we will further dissect ECR-4 (E8VI) and ECR-8 (E8I). For both ECRs,
that will be achieved with additional transgenic reporter assays, since we could not iden-
tify a T cell line in which E8I (Ellmeier et al., unpublished) or E8VI displays in vitro
enhancer activity . In addition we will generate ECR-4-deficient mice and the CD8 ex-
pression pattern in conventional T cells, IELs and DCs of E8VI-knock out mice will then
be analyzed in detail.
Conclusion
In this study, we have demonstrated that a bioinformatics approach is a powerful method
for complementing biological assays in the identification of cis-regulatory elements within
the genomic Cd8ab loci. By employing this approach we identified the core enhancer
region of E8I which is the first step in the isolation and identification of transcription
factors that regulate CD8 expression. Furthermore we identified a novel Cd8 enhancer
element E8VI that is active in mature CD8 SP thymocytes, in CD8 T cells as well as in
CD11c+ CD8αα+ DCs. E8VI is to our knowledge the first Cd8cis-element that is active
in CD8αα+ DCs.
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3.2 The transcription factors MAZR, Th-POK and RUNX
Previous studies have identified several transcription factors that are involved in the
regulation of coreceptor gene expression and CD4/CD8 cell fate decisions. We recently
demonstrated epigenetic control of the Cd8a and Cd8b gene loci by the transcription
factor MAZR.32 MAZR was isolated using a yeast one-hybrid screen in a search for
Cd8 enhancer E8II binding proteins and we showed that MAZR is a negative regulator
of CD8 expression during the DN to DP transition of thymocyte development.32 To
analyse the function of MAZR in more detail, we recently generated MAZR deficient
mice. An altered CD4/CD8 ratio in the thymus as well as the development of class
I-restricted CD4 lineage cells in MAZR -/- mice was observed (Sakaguchi et al., paper
in preparation). Real time PCR analysis of MAZR knockout mice also revealed a three
fold increase of Th-POK expression in MAZR -/- CD4+ Cd8lo thymocytes, indicating
that MAZR might regulate Th-POK expression. Therefore we analysed the interaction
of MAZR with other transcription factors such as Th-POK and RUNX that are known
to regulate CD4/CD8 cell fate decision.59 (Figure 3.3).
Figure 3.3: Regulation of Cd8 gene expression. Expression of the Cd8a gene is
controlled by the stage and lineage specific enhancer elements E8I-E8V. Transcription fac-
tors that bind to these regions include Ikaros31 (green), RUNX49 (yellow), MAZR32(blue)
and STAT5 (signal transducer and activator of transcription 5)60 (red).59
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Recent findings in our group indicate that the redirection in MAZR deficient mice was in-
duced by de-repressed expression of Th-POK. One possible molecular mechanism would
be that MAZR represses Th-POK expression via binding to the Th-POK silencer RBS-
1. To test our hypothesis, we searched the Th-POK silencer region RBS-1 for potential
MAZR binding sites and this lead to the identification of three MAZR target sequences.
By performing ChIP experiments we detected binding of MAZR to the Th-POK silencer
region RBS-1, and therefore providing a potential molecular mechanism.
Another transcription factor that is involved in CD4/CD8 lineage decision of DP thy-
mocytes is RUNX. RUNX is a negative regulator of Th-POK and previous studies have
shown that RUNX proteins bind to the Th-POK silencer region RBS-1. Therefore we
asked the question if MAZR is necessary for proper binding of RUNX3 to the Th-POK
silencer region RBS-1. ChIP experiments revealed that RUNX3 binding to the Th-POK
silencer region RBS-1 is independent of MAZR. Another ChIP experiment in RUNX
deficient mice showed, that the binding of MAZR to the Th-POK silencer region RBS-1
is weaker compared to wildtype mice (unpublished data). These results indicate that
MAZR is recruited to the Th-POK silencer region RBS-1 by the RUNX complex and
in turn contributes to the appropriate repression of Th-POK expression in cooperation
with the RUNX complex. Furthermore we could not detect a direct interaction between
MAZR and RUNX3 by using co-immunoprecipitation assays (data not shown). One
reason might be, that the in vitro conditions differ from those in vivo. Therefore we are
currently testing whether we can detect the interaction in ex vivo isolated thymocytes.
To gain more insights into the role of MAZR in CD4/CD8 lineage decision, we will
performed a DNA microarray analysis to compare the gene expression profile between
MAZR +/+ and –/– mice at the DP stage of thymocytes. This experiment will help
us to find new genes of transcription factors that might be involved in the regulation of
MAZR during cell fate decision processes.
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Conclusion
We have recently demonstrated epigenetic control of the Cd8a and Cd8b gene loci by
the transcription factor MAZR.32 In order to learn more about the role of MAZR, we
generated MAZR deficient mice and observed an altered CD4/CD8 ratio in the thymus
of MAZR knockout mice as well as the development of class I-restricted CD4 lineage
cells indicating altered lineage differentiation. Furthermore we observed an increase of
Th-POK expression in MAZR -/- CD4+CD8lo thymocytes, indicating that MAZR might
regulate the expression of Th-POK. In this study, we propose a molecular mechanism
where MAZR is recruited to the Th-POK silencer region RBS-1 via RUNX and in turn
contributes to the appropriate repression of Th-POK expression.
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4.1 Cell lines and culture
4.1.1 1200M cell line
1200M cells were cultivated in RPMI 1640 (Gibco) supplemented with 10% foetal calf
serum (Gibco) which was heat inactivated at 56°C for 40 min, 50µM ß-mercaptoethanol,
100 U/ml Penicillin, 0,3µg/ml L-Glutamine, and 100µg/ml Streptomycin.
BM cyclin was used for treatment of mycoplasma-contaminated 1200M cell cultures.
After splitting the cells 1:20 in a new cell culture flask, BM cyclin 1 stock solution
was added to reach a final concentration of 5µg/ml. 1200M cells were cultivated for 3
days, the medium was removed BM cyclin 2 was added to reach an end concentration
of 2µg/ml. The cells were cultivated for 4 days and the treatment was repeated twice.
4.1.2 AKR1.1 cell line
AKR1.1 cells were cultivated in RPMI 1640 (Gibco) supplemented with 10% foetal calf
serum (Gibco), 100 U/ml Penicillin, 0,3µg/ml L-Glutamine, and 100µg/ml Strepto-
mycin.
4.1.3 293T cell line
293T cells were cultivated in DMEM (Gibco) supplemented with 10% foetal calf serum
(Gibco), 100 U/ml Penicillin, 0,3µg/ml L-Glutamine, and 100µg/ml Streptomycin.
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4.1.4 Cell stocks
Suspension cells were centrifuged at 3200 rpm for 3 min and resuspended in 90% FCS
and 10% DMSO to reach a final concentration of 10x106 cells/ml. Cryotubes were in-
cubated in -80°C over night and finally stored in liquide nitrogen.
4.2 Bacterial Techniques
4.2.1 Bacteria LB-media (Luria/Miller)
25g of LB Media or 40g of LB Agar was resolved in 1l of deionized water and autoclaved
at 125°C for 1h. After autoclaving, the media was left to cool down to 55°C. For selection
of bacterial strains carrying plasmids with an ampicillin resistance gene, ampicillin was
added to a final concentration of 100µg/ml before inoculation. For solid media plates,
the LB Agar was poured into 10cm dishes, left at room temperature until the LB Agar
became solid and were finally stored at 4°C.
4.2.2 Preperation of competent E.coli cells
Competent cells were prepared by inoculating 3ml LB medium with the DH5α strain.
This culture was incubated by shaking at 200 rpm at 37°C over night. Next morning
100ml of LB medium was inoculated with 1ml of the over-night culture and incubated
on a shaker at 37°C until the OD600 reached 0,3-0,6. Then the cells were centrifuged at
5000 rpm for 5 min. The cell pellet was resuspended in 10ml sterile filtrated TBS buffer
(LB containing 10% Polyethylenglycol 3350, 5% Dimethylsulfoxid, 10mM MgCl2, and
10mM MgSO4). Then the cells were aliquoted in eppendorf tubes, snap frozen in liquide
nitrogen and stored at -80°C.
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4.2.3 Transformation
Transformation was performed by mixing 10µl ligation reaction with 100µl competent
E.coli cells (DH5α), 80µl dH2O and 20µl KCM-Buffer (0,5M KCl, 0,15M CaCl2 and
0,25M MgCl2). After an incubation of 40 min on ice and a following incubation for 10
min at RT, bacterial cells were plated out on LB-Amp (100µg/µl) plates and incubated
at 37°C, 0,5% CO2 overnight.
4.3 DNA Methodes
4.3.1 Restriction digest
Restriction digest was performed using 40 Units EcoRI restriction enzym (New England
Biolabs #R0101s), 10-15µl DNA templates, and 10x buffer EcoRI (Fermentas #B12) in
a volume of 50µl. The following incubation step was performed at 37°C for 2 h.
4.3.2 Ligation
Ligation of the PCR products was performed by mixing 50ng pGEM-T Easy vector
(Promega #TM042, Figure 4.1) with a 4 molar access of PCR products, dH2O, 5µl 1x
Rapid Ligation Buffer (Promega) and 3 Units T4 DNA Ligase (Promega) in a volume of
10µl. The ligation mix was incubated for 1,5 h at RT. DNA ligation was carried out with
30ng of the luciferase (WE310)- and transgenic vector (WE-191) and a 4 molar access
of inserts as estimated from the gel in a volume of 10µl. The reactions were incubated
with 3 Units T4 DNA Ligase (Promega) at 16°C for 3 h.
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Figure 4.1: pGEM-T Easy Vector circle map
4.3.3 PCR reactions
Genomic DNA was isolated from C57BL/6 ES cells using phenol/chloroform precipita-
tion. The evolutionary conserved regions (ECR-4, -5 and -9) were amplified with the
following forward and reverse primers:
Primer Sequence (5´to 3´)
ECR-4 forward ATGAATTCGACAACTCAAGGCCAGCAC
ECR-4 reverse ATGAATTCGGGGTGGGTGCTAGATGA
ECR-5 forward ATGAATTCTTTTTCAATTCCTGTCCGTGT
ECR-5 reverse ATGAATTCGCCTTGGAATCTTGATCCTC
ECR-9 forward ATGAATTCTCCCACACCAGAAAAAGAAGA
ECR-9 reverse ATGAATTCCCTAGGTTGTCCTTGAATTTACA
The underlined sequences indicating EcoRI restriction sites that were added on the
5´ end of the primer. ECR-4 has a length of 246bp and the PCR product was 497bp.
ECR-5 is 115bp and after PCR amplificaton the product size was 228bp, whereas ECR-9
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has a size of 119bp and after amplification it was 271bp.
The PCR reactions were performed on a PTC-200 Peltier Thermal cycler (MJ research)
under the following conditions: 1x Taq Buffer, 0,1µM of each primer, 0,2mM dNTP mix,
and DMSO in a volume of 25µl. For cloning purposes 2,5 U Taq DNA Polymerase (New
England Biolabs #M0267L) was used. The PCR program was as follows: 96°C for 5
min, 39 cycles at 94°C for 30 sec, 60°C for 30 sec, and 72°C for 2 min; and 72°C for 7
min. The PCR products were seperated on an 1% agarose gel.
For ChIP experiments the following forward and reverse primer were used:
Primer Sequence (5´to 3´)
RBS-1 forward TGGTTTCGAGACTGGCTGGT
RBS-1 reverse GACCGAGGAGCTGCTTTCAG
The PCR reactions were performed on a PTC-200 Peltier Thermal cycler (MJ research)
under the following conditions: 1x Taq Buffer (5 Prime), 0,1µM of each primer, 0,2mM
dNTP mix in a volume of 25µl. 2,5 U Taq DNA Polymerase (5 Prime) was used. The
PCR program was as follows: 96°C for 5 min, 35 cycles at 94°C for 30 sec, 58°C for 30
sec, and 72°C for 40 sec; and 72°C for 2 min. The PCR products were seperated on an
1% agarose gel.
4.3.4 Agarose Gel Electrophoresis
DNA fragments were separated on 1% agarose gels using 1 x TAE buffer (40mM Tris-
acetate, 1mM EDTA pH 8,3) as running and preparation buffer. 1-2 drops of ethidium-
bromide solution (0,08%) were added to the agarose gel solution. Samples were loaded
on the gel with 6x DNA loading Dye (10 mM Tris-HCl (pH 7.6), 0.03% bromophenol
blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA; Fermentas #R0611). Gen-
Ruler DNA Ladder Mix (Fermentas #SM0333) was used as DNA size marker and the
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gels were run at 100V. DNA bands were visualized with an UV illuminator and a Lumi-
Imager (Boehringer Mannheim), respectively.
4.3.5 Gel purification (Wizard SV Gel clean-Up system, Promega)
The fragments were cut out and 10µl Membran binding solution (per 10mg gel) was
added, vortexed and incubated at 55°C until the gel slice was completely dissolved.
The samples were transfered to the SV Minicolumn, incubated for 1 min at RT and
centrifuged at 16000 g for 1 min. 700µl Membran wash solution was added to the mini-
column and centrifuged at 16000 g for 1 min. Then 500µl Membran wash solution was
added to the minicolumn and centrifuged at 16000 g for 5 min. Finally, the empty
minicolumn was centrifuged at 16000 g for 1 min. DNA was eluated with 30µl dH2O,
incubated 1 min and centrifuged at 16000 g for 1 min. Samples were stored at -20°C.
4.3.6 Plasmid DNA Purification (Wizard Plus SV Miniprep DNA Purification
System, Promega)
1 ml of overnight cultures was centrifuged at 10000 g for 5 min to pellet the bacteria. All
centrifugation steps were done at room temperature. The cell pellet was resuspended in
250µl Cell Resuspension Solution. 250µl Cell Lysis Solution was added, the sample was
mixed by inverting 4 times and incubated until the cell suspension clears. 10µl Alkaline
Protease Solution was added, mixed by inverting the tube 4 times and incubated for 5
min. Next 350µl Wizard Plus SV Neutralization Solution was added and the sample
was mixed 4 times. The bacterial lysate was centrifuged at 14000 g for 10 min. The
lysate was transfered into the Spin Column and centrifuge at 14000 g for 1 min. 750µl
Wash Solution was added and the sample was centrifuge at 14000 g for 1 min. 250µl
Wash Solution was added and the sample was centrifuge at 14000 g for 1 min. To ensure
removal of ethanol the column was centrifuged at 14000 g for 2 min. In the final step
100µl dH2O was added and the Plasmid DNA was eluted by a final centrifugation step
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at 14000 g for 1 min.
4.3.7 Plasmid DNA Purification (Plasmid Maxi Kit, QIAGEN)
100 ml of LB medium was inoculated with 1 ml of competent bacterial cells and grown
overnight at 37°C. The bacterial cells were harvested by centrifugation at 5000 g for
15 min at 4°C. For efficient lysis the bacterial pellet was resuspended in 10 ml Buffer
P1 (Resuspension buffer) and was vortexed until no cell clumps remained. Then 10
ml Buffer P2 (Lysis buffer) was added, mixed gently by inverting 4-6 times until it ap-
peared viscous and was incubated at room temperature for 5 min. By adding 10 ml of
chilled buffer P3 (Neutralization buffer) and inverting 4-6 times a fluffy white material
formed, which contained genomic DNA, proteins, cell debris and SDS. The mixture was
then incubated on ice for 20 min. After this precipitation step the mixture was cen-
trifuged at 5000 g for 30 min at 4°C and the supernatant containing plasmid DNA was
removed promptly. In the intervening period the QIAGEN-tip 500 was equilibrated by
applying 10 ml Buffer QBT (Equilibration buffer). The supernatant was loaded onto
the QIAGEN-tip using a paper towel in addition and was allowed to enter the resin by
gravity flow. Then the QIAGEN-tip was washed with 30 ml Buffer QC (Wash buffer)
for two times. The washing steps are sufficient for removing all contaminants in the ma-
jority of plasmid DNA preparations. Afterwards the DNA was eluted with 15 ml Buffer
QF (Elution buffer), precipitated by adding 10.5 ml (0.7 volumes) isopropanol and was
centrifuged at 5000 g for 1 h at 4°C. The supernatant was removed and the DNA pellet
was washed with 5 ml of room-temperature 70% ethanol and was centrifuged 5000 g for
1 h. The resulting supernatant was removed again, the DNA pellet was air-dried for 10
min and redissolved in 200µl H2O.
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4.3.8 DNA purification using Phenol/Chloroform extraction and ethanol
precipitation
An equal volume of Phenol-Chloroform-Isoamyethanol (23:24:1) was added to the DNA
sample, mixed and centrifuged at 12000 rpm for 5 min at 4°C. The supernatant was
transfered to a fresh tube. Next an equal volume of Chloroform was added, the sample
was mixed and centrifuged at 12000 rpm for 5 min at 4°C. The supernatant was removed
and 20µg of glycogen was added in order to visualize the small DNA pellet. 0.1 volume
of 5M NaCl and 2.5 volumes of ice cold 100% Ethanol were added to precipitate DNA,
mixed and centrifuged at 12000 rpm for 20 min at 4°C. The supernatant was removed,
1 ml 70% Ethanol was added and centrifuged at 12000 rpm for 10 min at 4°C. The
supernatant was removed again and the DNA pellet was air dried for 10 min at room
temperature. Finally the DNA was resuspended in an appropriate amount of dH2O.
4.3.9 Generation of transgenic constructs
The generation of the basic Cd8a promoter-human CD2 (hCD2) reporter construct has
been previously described.21 ECR-4 and -5 were amplified by PCR and subcloned into
the Cd8a promoter-hCD2 reporter construct as described above (Figure 4.2).
Figure 4.2: Schematic map of the transgenic reporter construct used for the
generation of TG mice. The basic construct contains part of the first Cd4 intron as
a splicing module between the Cd8a promoter and the human CD2 reporter gene (not
shown). Inserted genomic fragments are shown in yellow, Cd8a promotor in grey, hCD2
reporter gene in blue and poly-A in grey.
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4.3.10 Generation of transgenic mice
F2 eggs of (B6/D2) mice were injected with the transgenic constructs according to stan-
dard procedures . Transgenic founders were identified by Southern blotting of tail DNA
with a probe from the CD4 splicing module of the transgenic reporter construct. Trans-
genic animals were backcrossed to C57BL/6 to generate transgenic lines. All animals
analyzed were between 4 and 16 wk old. Transgenic mice were generated at the RCAI
in Yokohama, Japan.
4.3.11 Transfection of 293T cells
Frozen 293T cells were thawed and washed with 50 ml of 293T medium. The follow-
ing centrifugation step at 1400 rpm for 4 min removed DMSO which is included in
the freezing medium and is toxic for the cells. The supernatant was sucked off, 40 ml
of new 293T medium was added and 4x10 ml was transfered to a 10cm2 tissue plate
(Corning) to reach a dilution of 1/4. After 2 days the cell culture medium was sucked
off and the confluent cells were washed with 5 ml PBS. After this washing step, 2 ml
Trypsin was added, the cells were incubated at 37°C for 5 min and a following centrifu-
gation step at 1400 rpm for 4 min was performed. The supernatant was removed, cells
were counted with a Casy counter and 3x106 cells were seeded to a 10cm2 tissue plate.
The next morning 10µg of myc-RUNX3 and/or full length MAZR was transfered into
a polystyrene round bottom tube (BD falcon) and mixed with 200µl 1,25M CaCl2 and
790µl dH2O. Using a pasteur pipet, bubbles of the samples were formed and 1 ml 2xHBS
buffer was added dropwise. The samples were then vortexed, incubated for 2 min on ice
and transfered slowly to the 10cm2 tissue plates. After 6 hours the media was sucked
off, the cells were washed with 5 ml PBS and 10 ml 293T medium was added. After
48 hours the supernatant was removed and the cells were washed twice with ice cold 1x
PBS. A Cell Scraper (Greiner-Bio one) was used to remove adherent cells and the cells
were collected in a 15 ml tube (Iwaki). The samples were then centrifuged at 14000 rpm
for 4 min, the supernatant was sucked off and the cells were resuspended in 250µl Carin
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Lysis Buffer (20mM Tris HCl, pH 8.0, 138mM NaCl, 10mM EDTA, 100mM NaF, 1%
NP40, 10% glycerol, 2mM Na-Ortho-Vanadate and Proteaseinhibitor). Finally the cells
were transfered to screwed cryo tubes, immediately frozen in liquide nitrogen and stored
at -80°C.
4.4 Protein Analysis
4.4.1 SDS polyacrylamide gel Electrophoresis (SDS-page)
Protein samples were mixed with 4x Laemmli buffer (250mM Tris-base (pH 6.8), 8%
SDS, 20% ß-mercaptoethanol, 43,4% glyerol), boiled at 95°C for 10 min and spinned
down before loading on the gel. The denatured protein samples were separated on an
8% polyacrylamide gel using 1x running buffer (25mM Tris-base, 192mM glycine, and
0.1% sodium dodecyl sulfat) at 60 Volt for stacking gel and 120 Volt for resolving gel,
respectively. 7µl PageRuler prestained protein ladder (Fermentas) was used to deter-
mine the fragment length of the protein samples.
4.4.2 Western Blot
After SDS polyacrylamide gel electrophoresis, proteins were transfered to ImmobilonP
polyvinyl difluorid (PVDF) membranes (Millipore) using a wet blot transfer system.
The PVDF membranes were equilibrated in methanol and sandwiched with the poly-
acrylamide gel between 2 layers of wattmann papers and 2 layers of sponges. For the
transfer process 200 mA constant current was used for 2 hours at 4°C. After the transfer,
PVDF membranes were blocked in Tris-buffered saline (TBST) (50mM Tris-HCl pH 8,
100mM NaCl, 0,1% Tween-20) with 5% non-fat dried milk at room temperature for 1
hour and at 4°C over night, respectively. Then the membranes were incubated with
MAZR serum (1:7500) and anti-myc antibody (1:5000)diluted in TBST containing 3%
non fat dried milk for total protein at room temperature for 1 hour, washed with TBST
6 times for 10 min, incubated with the secondary horseradish peroxidase (HRP)-coupled
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anti-rabbit (1:5000) antibody, diluted in TBST containing 1% non fat dried milk at room
temperature for 1 hour and finally washed with TBST 6 times for 10 min. Immunoblots
were developed using enhanced chemilumiscent (ECL) reagent (Amersham) and imaged
on high performance chemiluminescent films (Hyperfilm, ECL, Amersham). Blots were
re-probed with antibodies recognizing total protein after stripping in Stripping buffer
(62.5mM Tris-HCl pH 7.5, 100mM ß-mercaptoethanol, 2% SDS) for 15 min at 60°C.
4.4.3 ChIP (Chromatin Immunoprecipitation)
6-8 weeks old wildtype (C57BL/6) and MAZR deficient mice (males and females) were
humanely killed by cervical dislocation. The thymus was isolated and homogenized in
3 ml PBS/1% FCS by using a syringe element in combination with a cell strainer. The
single cell suspension was transfered into a new 50 ml falcon tube, 1ml PBS/1% FCS
was added and the sample was centrifuged at 1600 rpm for 4 min at 4°C. Next the
supernatant was removed and 1 ml of Ack lysis buffer (9 volumes 0,83% NH4Cl + 1
volume Tris pH 7.65) was added to lyse erythrocytes. The sample was mixed, incubated
for 2 min at RT and 10 ml PBS/1%FCS was added. The sample was transfered to a
new 50 ml falcon using a cell strainer and centrifuged at 1600 rpm for 3 min at 4°C. The
supernatant was decanted, 10 ml PBS/1%FCS was added and thymocytes were counted
with the Casey cell counter.
1x107 thymocytes were centrifuged at 1200 rpm for 5 min and washed twice in ice
cold 1x PBS/1mM PMSF. For crosslinking, the cells were resuspended in 10 ml of
0,6% formaldehyde solution in PBS + Proteaseinhibitor (PI). The samples were placed
immediately on 37°C for 2:30 min. The crosslinking was stopped by addition of 500µl
2,5M glycine, the tubes were inverted several times and incubated on a rotating wheel
for 5 min at room temperature. Next, thymocytes were centrifuged at 3200 rpm for 5
min at 4°C. To remove formaldehyde, the cells were washed with 10 ml of ice cold PBS
+ PI twice. In the final wash step, the supernatant was removed and the pellets were
snap frozen on dry ice for several minutes. Afterwards the cell pellets were resuspended
in 500µl lysis buffer (50mM Tris ph 8.0, 10mM EDTA, 1% SDS, PI) and incubated on
44
4 Materials and Methods
ice for 20 min.
The lysates were sonicated using a Bandelin Sonoplus 70 Sonicator with the following
settings: 7x10 sec intervals at 30% power. Between the sonication intervalls a 20 sec
break on ice was performed. In case of foaming, the samples were spinned down, the
foam was removed and dH2O was added to a final volume of 500µl. The sonicator tip was
washed with 70% EtOH and dH2O prior to sonicating different samples. The sonicated
lysates were centrifuged at 13000 rpm for 10 min at 4°C to pellet the cell debris. 400µl
of sonicated supernatant was transfered into a new 15 ml falcon tube and 3,6 ml Chip
buffer (0,01% SDS, 1,1% Triton X-100, 1,2mM EDTA, 16,7mM Tris pH 8.0, 167mM
NaCl, PI) was added. Then the sample was split: 40µl (input sample) was transfered
in a new 1,5 ml eppendorf tube and stored at -20°C. 2 x 1980µl were split into new 2
ml eppendorf tubes and correspond to the Chip sample and negative control sample. In
addition the remaining 100µl of lysate was filled up to 500µl with H2O, 20µl of 5M NaCl
was added and the sample was decrosslinked o/n at 65°C while shaking.
80µl of ssDNA/Protein A (for rabbit anti-MAZR and rabbit anti-CBFb2) Agarose slurry
was added to the Chip and negative control samples and rotated 45 min at 4°C to preclear
the lysates from proteins that unspecifically bind to the Agarose slurry and protein A.
The agarose slurry was then centrifuged at 1000 rpm for 1 min and the supernatant was
transfered to a new 2 ml eppendorf tube. 10µl MAZR Preserum or dH2O was used as
negative control and 10µl MAZR-serum or 20µl (10µg) CBFb2 serum was added to the
samples following an incubation overnight at 4°C with gentle rotation. The next day 60µl
of ssDNA/Protein A/Agarose slurry was added to precipitate specific DNA-protein-Ab
complexes and the samples were rotated gently for 1,5 - 2 hours at 4°C. A centrifugation
step at 1000 rpm for 1 min at 4°C was performed to pellet down the agarose beads. The
supernatant was removed and the following washing steps were performed by rotating
the samples for 3-5 min at 4°C and centrifugation at 1000 rpm for 1 min: 1) 1 ml of
ice-cold Low Salt wash buffer (0,1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH
8.0, 150mM NaCl, PI), 2) 1 ml of ice-cold High Salt wash buffer (0,1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris pH 8.0, 500mM NaCl, PI), 3) 1 ml of ice-cold LiCl
immunocomplex wash buffer (0,25M LiCl, 1% NP40, 1% Deoxycholate, 1mM EDTA,
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10mM Tris pH 8.0, PI), 4) 2x with 1 ml of ice-cold 1xTE (10mM Tris pH 8.0, 1mM
EDTA, PI). Afterwards the DNA-histone complex was eluted from the antibodies by
adding 250µl of Elution buffer (1% SDS, 0,1M NaHCO3) to the agarose slurry/protein
A/histone complex. The samples were shortly vortexed and shook for 15 min at RT.
The agarose beads were centrifuged at 1000 rpm for 1 min at RT and the supernatant
was collected. The elution step was repeated again to collect a total of 500µl eluate and
the input samples were filled up with 460µl dH2O to a total of 500µl. 20µl of 5M NaCl
was added and the samples were reverse crosslinked at 65°C o/n while shaking. The
next day 10µl 0,5M EDTA, 20µl 1M TRIS-HCl pH 6.5 and 2µl of 10mg/ml Proteinase
K was added to the reverse crosslinked eluate and incubated for 1 hour at 45°C. Finally,
DNA was isolated by using Phenol/Chloroform precipitation as described above. All
steps were performed by using filter tips.
4.4.4 Co-Immunoprecipitation
Frozen transfected cells were thawed on ice and centrifuged at 13000 rpm for 20 min at
4°C. For Western blotting 30µl of samples were mixed with 10µl Laemmli Buffer and
frozen in liquide nitrogen. The rest of the lysates were filled up to 500µl with Carin-
Lysisbuffer (20mM Tris HCl, pH 8.0, 138mM NaCl, 10mM EDTA, 100mM NaF, 1%
NP40, 10% glycerol, 2mM Na-Ortho-Vanadate and Proteaseinhibitor). In the interven-
ing period a 30% protein G sepharose was prepared. Following a washing step with
Carin lysis buffer, 50µl 30% protein G sepharose was transfered to the IP samples and
incubated for 1 hour at 4°C on a rotating wheel. After a centrifugation step at 1200
rpm for 1 min at 4°C, the supernatant was removed and 10µg of α-myc-Ab was added.
Then the samples were incubated overnigt at 4°C on a rotating wheel.
The next day another 50µl 30% protein G sepharose was added to the samples and
rotated for 1 hour at 4°C. After a centrifugation step at 1500 rpm for 1 min at 4°C the
supernatant was sucked off and 1 ml Carin Lysis buffer was added. The samples were
mixed, centrifuged at 1500 rpm for 1 min at 4°C. The washing steps were done in a
total of four times. 30µl Carin Lysis buffer and 10µl Laemmli Buffer were added to the
samples. Finally, the samples were boiled at 95°C for 10 min and centrifuged at 132000
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rpm for 10 min at 4°. The supernatant was frozen in liquide nitrogen and either stored
at -80°C or used immediately for SDS page. Western blotting was performed due to the
protocol describes above.
4.5 Biological assays
4.5.1 Luciferase assay
1200M cells (5x106cells/500µl of RPMI 1640, 25µM Hepes) were electroporated (960µF,
220V; Bio-Rad Gene Pulser) in 0.4 cm cuvettes (Bio-Rad) with either 10 µg WE310 +
ECR4 or an equimolar amount of plasmids WE310 + ECR-5, -9 or WE511. (Figure 4.3)
Figure 4.3: Schematic map of the luciferase reporter construct used for lu-
ciferase assays. The basic construct contains part of the first Cd4 intron as a splicing
module between the Cd8a promoter and the luciferase reporter gene (not shown) . Ge-
nomic fragments (yellow) were inserted upstream of the Cd8a promoter. Cd8a promotor
is indicated in grey, luciferase reporter gene in green and poly-A in grey.
In addition 2 µg of SV40 Renilla-luciferase plasmid (Promega) was cotransfected to
normalize the transfection efficiency. The total amount of transfected DNA was equal
for each transfection and adjusted by adding dH2O. After electroporation, the cells were
washed with RMPI 1640 medium and finally cultured in 15 ml of 1200M medium (RPMI
1640, 10% FCS, and antibiotics). After 24-36 hours the luciferase activity was measured
using the Dual luciferase reporter assay system (Promega). The cells were transfered to
a 15 ml falcon and centrifuged at 1300 rpm for 5 min, RT. The supernatant was removed
and the cells were washed with PBS. After another centrifugation at 1300 rpm for 5 min,
100µl of passive lysis buffer (5x stock) was added to the pelleted cells and incubated for
10 min on ice. The cells were centrifuged at 5000 rpm for 20 min at 4°C and 20µl of
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the supernatant was transfered to a 5ml tube (Sarstedt). The samples were measured in
duplicates. 100µl luciferase reagent II was added and the firefly luciferase activity was
measured using a Luminometer. For the Renilla Luciferase activity 100µl of Stop and
glo solution (50x stock) was used.
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